Mini Review
Published on 02 May 2024
Nanoparticle-enhanced PD-1/PD-L1 targeted combination therapy for triple negative breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1393492
- 1,718 views
Type at least 3 characters
1,769 articles
Articles
Correction
Published on 01 May 2024
Corrigendum: The role of microtubules in pancreatic cancer: therapeutic progress
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1414456
- 561 views
Original Research
Published on 30 Apr 2024
MK591 (Quiflapon), a 5-lipoxygenase inhibitor, kills pancreatic cancer cells via downregulation of protein kinase C-epsilon
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1387535
- 1,178 views
Review
Published on 25 Apr 2024
Mechanisms of TREM2 mediated immunosuppression and regulation of cancer progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1375729
- 2,227 views
- 1 citation
Editorial
Published on 19 Apr 2024
Editorial: Emerging anti-cancer compounds and immunomodulators for pancreatic cancer treatment
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1411836
- 788 views
Clinical Trial
Published on 19 Apr 2024
Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1386190
- 1,726 views
Review
Published on 18 Apr 2024
Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1389713
- 1,494 views
- 3 citations
Brief Research Report
Published on 18 Apr 2024
Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1344852
- 1,835 views
Case Report
Published on 08 Apr 2024
Sunitinib for adenocarcinoma of the rete testis: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1358133
- 880 views
Case Report
Published on 04 Apr 2024
Efficacy of befotertinib in non-small cell lung cancer harboring uncommon compound EGFR mutations G719X and S768I: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1370666
- 1,109 views
- 2 citations
Review
Published on 28 Mar 2024
Therapeutic prospects of nectin-4 in cancer: applications and value
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1354543
- 7,382 views
- 4 citations
Original Research
Published on 25 Mar 2024
Pan-cancer and single-cell analyses identify CD44 as an immunotherapy response predictor and regulating macrophage polarization and tumor progression in colorectal cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1380821
- 2,990 views
- 2 citations
Retraction
Published on 20 Mar 2024
Retraction: Establishment of criteria for molecular differential diagnosis of MPC and IPM
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1399853
- 696 views
Original Research
Published on 14 Mar 2024
DDX58 deficiency leads to triple negative breast cancer chemotherapy resistance by inhibiting Type I IFN-mediated signalling apoptosis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1356778
- 1,810 views
- 1 citation
Case Report
Published on 14 Mar 2024
Case report: Targeted treatment strategies for Erdheim-Chester disease
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1305518
- 1,835 views
Case Report
Published on 11 Mar 2024
Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2024.1363069
- 1,630 views